Pre Solange Peters
MD, PhD
Professeure ordinaire UNIL
Cheffe du Département d'oncologie clinique
Cheffe du Service d'oncologie médicale
Responsable de la Consultation spécialisée des tumeurs thoraciques
Intérêts cliniques ou académiques
Spécialisations
Tumeurs thoraciques, cancers pulmonaires et tumeurs pleurales. Les tumeurs thoraciques incluent:
- Cancer bronchique non à petites cellules
- Cancer bronchiques à petites cellules
- Carcinoïdes bronchiques
- Tumeurs thymiques
- Mesotheliomes
- Tumeurs pleurales
- Métastases intrathoraciques
Activités de recherche
Recherche fondamentale qui se focalise principalement sur les nouveaux biomarqueurs et leur validation au sein des procédures, études précliniques et cliniques, et enfin recommandations pour la prise en charge des patient-es au niveau européen.
Pre Peters est également active dans les approches innovatives en termes de traitements multimodaux (radiothérapie, chimiothérapie et chirurgie) et gère l’organisation et la coordination d’essais cliniques, ainsi que les bases de données de l’European Thoracic Oncology Platform (ETOP). Cette large plateforme permet à ce jour d'étudier de multiples approches nouvelles dans le traitement des tumeurs thoraciques dans le monde.
Études cliniques sélectionnées en cours
- Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial. SAKK 16/08
- A randomized phase III trial evaluating the addition of Denosumab to standard first-line anticancer treatment in advanced NSCLC. Survival improvement in Lung cancer induced by Denosumab therapy ETOP/EORTC SPLENDOUR
- A randomized phase II trial of consolidation ipilimumab vs observation in stage I-III ("limited disease") small cell lung cancer after chemoradiotherapy ETOP STIMULI
Formation
- 2019: Professeure ordinaire (UNIL)
- 2016: Professeure associée (UNIL)
- 2006/12: European Society for Medical Oncology (ESMO) examen en oncologie
- 2006/10/12: Certficat de bonnes pratiques pour investigateurs et coordinateurs d'études-Swissmedic niveau 1-3
- 2006: Société Suisse d'oncologie médicale, examen oral
- 2002: PhD
- 1998: Doctorat en médecine
Langues
- Français
- Allemand
- Italien
- Anglais
Age des patients
- Adultes
Publications scientifiques sélectionnées
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON
Peters S, Oliner KS, L'Hernault A, Ratcliffe M, Madison H, Lai Z, Stewart R, Mann H, Lowery C, Garon EB, Mok T, Johnson ML
ESMO OpenDurvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML
J Thorac OncolLong-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS
J Thorac OncolLurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer
Dómine Gómez M, Subbiah V, Peters S, Sala MA, Trigo J, Paz-Ares L, Nieto Archilla A, Gomez Garcia J, Alvarez García C, López-Vilariño de Ramos JA, Kahatt Lopez C, Fernandez CM
Expert Rev Anticancer TherImmunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study
Weller M, Le Rhun E, Tsamtsouri L, Dummer R, Guckenberger M, Ribi K, di Giacomo AM, Minuti G, Collazo-Lorduy A, Brandsma D, O'Brien M, Ermis E, Fischer N, Ascierto P, Mandala M, Minniti G, Iranzo P, Roschitzki-Voser H, Ruepp B, Grolimund E, Dafni U, Peters S, Stahel R, ETOP 19-21 USZ-STRIKE collaborators
Lung CancerAdjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
Uprety D, Roden AC, Peters S
J Thorac OncolFirst-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK
J Clin OncolLandscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types
Semaan K, Nawfal R, Nally E, Janjigian YY, Robert C, Peters S, Powles T, Choueiri TK
Lancet OncolPrevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project
Haberecker M, Rüschoff JH, Andriakopoulou C, Gray SG, Nackaerts K, De Perrot M, Brcic L, Nadal E, Tsimpoukis S, Ampollini L, Aerts JG, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, Von Der Thüsen J, Vagenknecht P, Tsourti Z, Kerr KM, Kammler R, Peters S, Baas P, Opitz I, Stahel RA, Curioni-Fontecedro A, ETOP Mesoscape Consortium, TransSCOT Consortium
JCO Precis OncolHyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Hao Y, Gkasti A, Managh AJ, Dagher J, Sifis A, Tiron L, Chriqui LE, Marie DN, De Souza Silva O, Christodoulou M, Peters S, Joyce JA, Krueger T, Gonzalez M, Abdelnour-Berchtold E, Sempoux C, Clerc D, Teixeira-Farinha H, Hübner M, Meylan E, Dyson PJ, Cavin S, Perentes JY
Cancer Immunol ResDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B
J Immunother CancerProceedings of the 1st biannual bridging the gaps in lung cancer conference
Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E
OncologistAntibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A, Addeo A, Peters S, Remon J
Cancer Treat RevImmunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Wang Y, Safi M, Hirsch FR, Lu S, Peters S, Govindan R, Rosell R, Park K, Zhang JJ
Nat Rev Clin Oncol
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA, ETOP 10-16 BOOSTER Collaborators
Clin Cancer ResSafety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, O'Brien M, Paz-Ares L, Peters S, Powles T, Leiby MA, Lin J, Zhao Y, Krepler C, Perini RF, Catherine Pietanza M, Samkari A, Gruber T, Ibrahim N, Eggermont AMM
Eur J CancerEntrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R
Nat MedBrief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
Kulkarni AA, Hennessy C, Wilson G, Ramesh V, Hwang C, Awosika J, Bakouny Z, Khan H, Vilar-Compte D, McKay R, Jani C, Weissmann L, Griffiths E, Batist G, Bouganim N, Mavromatis B, Bashir B, Nguyen RH, Riess JW, Puc M, Kasi A, Berg S, Castillo DR, Hayes-Lattin B, Hosmer W, Flora D, Mishra S, French B, Warner JL, Lopes G, Peters S, Florez N
Clin Lung CancerA pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial
Bandiera C, Cardoso E, Locatelli I, Zaman K, Diciolla A, Digklia A, Stravodimou A, Cristina V, Aedo-Lopez V, Dolcan A, Sarivalasis A, Bouchaab H, Pasquier J, Dotta-Celio J, Peters S, Wagner D, Csajka C, Schneider MP
PLoS OneNTRK gene fusion testing and management in lung cancer
Repetto M, Chiara Garassino M, Loong HH, Lopez-Rios F, Mok T, Peters S, Planchard D, Popat S, Rudzinski ER, Drilon A, Zhou C
Cancer Treat RevBeyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges
Mountzios G, Naidoo J, Wang C, Creelan BC, Trotier DC, Campbell TC, Peters S
Am Soc Clin Oncol Educ BookL’immunothérapie en oncologie : entre espoirs, défis et équité
Peters S, Addeo A, Herrera FG
Rev Med SuisseA Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML
Clin Lung CancerPrimary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M
Nat CommunLong-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis
Kinj R, Hottinger AF, Böhlen TT, Ozsahin M, Vallet V, Dunet V, Bouchaab H, Peters S, Tuleasca C, Bourhis J, Schiappacasse L
Cancers (Basel)Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, Del Nagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N
Clin Cancer ResAdjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now
Passaro A, Peters S
N Engl J MedCancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S
CellLung Cancer in Switzerland
Werner RS, Curioni-Fontecedro A, Mauti LA, Addeo A, Peters S, Frauenfelder T, Puhan MA, Haberecker M, Bubendorf L, Finazzi T, Guckenberger M, Cafarotti S, Geiser T, Opitz I, SAKK
J Thorac OncolLurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Peters S, Trigo J, Besse B, Moreno V, Navarro A, Eugenia Olmedo M, Paz-Ares L, Grohé C, Antonio Lopez-Vilariño J, Fernández C, Kahatt C, Alfaro V, Nieto A, Zeaiter A, Subbiah V
Lung CancerFirst-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety D, Remon J, Peters S
J Clin OncolOncology: what's new in 2023
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, Stravodimou A
Rev Med SuissePhase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis
Chriqui LE, Abdelnour-Berchtold E, Zanfrini E, Devesa-Perez S, Gonzalez M, Krueger T, Ellefsen K, Destaillats A, Bonnet D, Hübner M, Bouchaab H, Bassani-Sternberg M, Peters S, Cavin S, Perentes JY
Cancer Treat Res CommunFace to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)
Gridelli C, Peters S, Mok T, Garassino M, Paz-Ares L, Attili I, de Marinis F
Lung CancerThe KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, Garassino MC, Sands J, Keenan T, Zhao B, Healy J, Ahn MJ
Future OncolCalls to action on lung cancer management and research
Meyer ML, Hirsch FR, Bunn PA, Ujhazy P, Fredrickson D, Berg CD, Carbone DP, Halmos B, Singh H, Borghaei H, Ferris A, Langer C, Dacic S, Mok TS, Peters S, Johnson BE
OncologistIdentifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study
Jolidon V, Eicher M, Peytremann-Bridevaux I, Aebi S, Anchisi S, Bettini A, Chalandon Y, Dietrich PY, Duchosal MA, Dürr D, Peters S, von Moos R, Wicki A, Arditi C
CancerCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ross A Soo 1, Urania Dafni 2 3, Ji-Youn Han 4, Byoung Chul Cho 5, Ernest Nadal 6, Chong Ming Yeo 7, Enric Carcereny 8, Javier de Castro 9, Maria Angeles Sala 10, Linda Coate 11, Mariano Provencio 12, Christian Britschgi 13, Patrick Vagenknecht 14, Georgia Dimopoulou 3, Roswitha Kammler 14, Stephen P Finn 15, Solange Peters 16, Rolf A Stahel 17; ETOP 10-16 BOOSTER Collaborators
Clin Cancer Res . 2024 Nov 15;30(22):5180-5191.KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Jan Budczies 1 2 3, Eva Romanovsky 4, Martina Kirchner 4, Olaf Neumann 4, Miriam Blasi 5 6, Johannes Schnorbach 5 6, Rajiv Shah 5 6, Farastuk Bozorgmehr 5 6, Rajkumar Savai 7 8, Thorsten Stiewe 9, Solange Peters 10, Peter Schirmacher 4 11, Michael Thomas 5 6, Daniel Kazdal 4 11 5, Petros Christopoulos 5 6, Albrecht Stenzinger
Br J Cancer . 2024 Aug;131(3):524-533.ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project
Ernst-Jan M Speel 1, Urania Dafni 2, Erik Thunnissen 3, Jan Hendrik Rüschoff 4, Cathal O'Brien 5, Jacek Kowalski 6, Keith M Kerr 7, Lukas Bubendorf 8, Irene Sansano 9, Leena Joseph 10, Mark Kriegsmann 11, Atilio Navarro 12, Kim Monkhorst 13, Line Bille Madsen 14, Javier Hernandez Losa 9, Wojciech Biernat 6, Albrecht Stenzinger 11, Andrea Rüland 1, Lisa M Hillen 1, Nesa Marti 15, Miguel A Molina-Vila 16, Tereza Dellaporta 17, Roswitha Kammler 15, Solange Peters 18, Rolf A Stahel 19, Stephen P Finn 5, Teodora Radonic 3; Lungscape Consortium (see Appendix)
Lung Cancer . 2024 Aug:194:107860.New promises and challenges in the treatment of advanced non-small-cell lung cancer
May-Lucie Meyer 1, Bailey G Fitzgerald 2, Luis Paz-Ares 3, Federico Cappuzzo 4, Pasi A Jänne 5, Solange Peters 6, Fred R Hirsch 7
Lancet . 2024 Aug 24;404(10454):803-822.Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies # 1 2 3, Daniel Kazdal # 4 5 6, Michael Menzel 4 6, Susanne Beck 4 6, Klaus Kluck 4 6, Christian Altbürger 4 6, Constantin Schwab 4 6, Michael Allgäuer 4 6, Aysel Ahadova 7 8, Matthias Kloor 7 8, Peter Schirmacher 4 6, Solange Peters 9, Alwin Krämer 10 11, Petros Christopoulos 5 12, Albrecht Stenzinger
Nat Rev Clin Oncol . 2024 Oct;21(10):725-742. doi: 10.1038/s41571-024-00932-9. Epub 2024 Aug 27.Multicenter Study on Tumor Budding in Lung Squamous Cell Carcinoma: Comparison Between Biopsy and Resection With Interobserver Variability Assessment
Marie Maillard 1, Christina Neppl 2, Philipp Zens 3, Julie Anex 1, Solange Peters 4, Thorsten Krueger 5, Sabina Berezowska 6
Mod Pathol . 2024 Oct;37(10):100571.CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis 1, Haniel A Araujo # 2, Minh Truong Do # 2, Yu Qian 2, Xin Sun 2, Ana Galan-Cobo 2, John T Le 2, Meagan Montesion 3, Rachael Palmer 4, Nadine Jahchan 4, Joseph M Juan 5, Chengyin Min 6, Yi Yu 6, Xuewen Pan 6, Kathryn C Arbour 7, Natalie Vokes 2, Stephanie T Schmidt 8, David Molkentine 2, Dwight H Owen 9, Regan Memmott 9, Pradnya D Patil 10, Melina E Marmarelis 11, Mark M Awad 12, Joseph C Murray 13, Jessica A Hellyer 14, Justin F Gainor 15, Anastasios Dimou 16, Christine M Bestvina 17, Catherine A Shu 18, Jonathan W Riess 19, Collin M Blakely 20, Chad V Pecot 21, Laura Mezquita 22, Fabrizio Tabbó 23, Matthias Scheffler 24, Subba Digumarthy 25, Meghan J Mooradian 15, Adrian G Sacher 26, Sally C M Lau 27, Andreas N Saltos 28, Julia Rotow 12, Rocio Perez Johnson 29, Corinne Liu 29, Tyler Stewart 30, Sarah B Goldberg 31, Jonathan Killam 32, Zenta Walther 33, Kurt Schalper 33, Kurtis D Davies 34, Mark G Woodcock 21, Valsamo Anagnostou 13, Kristen A Marrone 13, Patrick M Forde 13, Biagio Ricciuti 12, Deepti Venkatraman 12, Eliezer M Van Allen 12, Amy L Cummings 35, Jonathan W Goldman 35, Hiram Shaish 18, Melanie Kier 36, Sharyn Katz 11, Charu Aggarwal 11, Ying Ni 10, Joseph T Azok 10, Jeremy Segal 37, Lauren Ritterhouse 3, Joel W Neal 14, Ludovic Lacroix 38, Yasir Y Elamin 2, Marcelo V Negrao 2, Xiuning Le 2, Vincent K Lam 13, Whitney E Lewis 2, Haley N Kemp 2, Brett Carter 39, Jack A Roth 40, Stephen Swisher 40, Richard Lee 2, Teng Zhou 2, Alissa Poteete 2, Yifan Kong 2, Tomohiro Takehara 2, Alvaro Guimaraes Paula 2, Edwin R Parra Cuentas 41, Carmen Behrens 41, Ignacio I Wistuba 41, Jianjun Zhang 2, George R Blumenschein 2, Carl Gay 2, Lauren A Byers 2, Don L Gibbons 2, Anne Tsao 2, J Jack Lee 42, Trever G Bivona 20, D Ross Camidge 43, Jhannelle E Gray 28, Natasha B Leighl 26, Benjamin Levy 13, Julie R Brahmer 13, Marina C Garassino 17, David R Gandara 19, Edward B Garon 35, Naiyer A Rizvi 44, Giorgio Vittorio Scagliotti 45, Jürgen Wolf 24, David Planchard 38, Benjamin Besse 38, Roy S Herbst 31, Heather A Wakelee 14, Nathan A Pennell 10, Alice T Shaw 46, Pasi A Jänne 12, David P Carbone 9, Matthew D Hellmann 47, Charles M Rudin 7, Lee Albacker 3, Helen Mann 48, Zhou Zhu 48, Zhongwu Lai 48, Ross Stewart 48, Solange Peters 49, Melissa L Johnson 50, Kwok K Wong 51, Alan Huang 6, Monte M Winslow 5 14, Michael J Rosen 5, Ian P Winters 5, Vassiliki A Papadimitrakopoulou 52, Tina Cascone 2, Philip Jewsbury 48, John V Heymach 53
Nature . 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9.Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
Aakash Desai 1, Vivek Subbiah 2, Sinchita Roy-Chowdhuri 3, Ajay Sheshadri 4, Sameer Deshmukh 1, Solange Peters 5
Cancers (Basel) . 2024 Nov 7;16(22):3753. doi: 10.3390/cancers16223753.
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges
Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC, Peters S
Nat Rev Clin OncolPD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA
J Immunother CancerPatient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Santorelli ML, Pietanza MC, Rudin CM
JTO Clin Res RepEuropean Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database
Opitz I, Bille A, Dafni U, Nackaerts K, Ampollini L, de Perrot M, Brcic L, Nadal E, Syrigos K, Gray SG, Aerts J, Curioni-Fontecedro A, Rüschoff JH, Monkhorst K, Weynand B, Silini EM, Bavaghar-Zaeimi F, Jakopovic M, Llatjos R, Tsimpoukis S, Finn SP, Von der Thüsen J, Marti N, Dimopoulou G, Kammler R, Peters S, Stahel RA, Falcoz PE, Brunelli A, Baas P; ETOP Mesoscape and ESTS Consortia
J Thorac OncolFirst-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Kristian Vollan H, Peters S
LancetAdjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review
Passaro A, Mok TSK, Attili I, Wu YL, Tsuboi M, de Marinis F, Peters S
JAMA OncolSystemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J, Gupta RG, Grootendorst DJ, Eccles LJ, Brahmer JR
J Thorac OncolAntibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
Passaro A, Jänne PA, Peters S
J Clin OncolThe Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies
Sun X, Abrahamson P, Ballew N, Kalilani L, Phiri K, Bell KF, Slowley A, Zajac M, Hofstatter E, Stojadinovic A, Silvestro A, Wang Z, Aziez A, Peters S
Cancer InvestCytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies
Godinho R, Noto A, Fenwick C, Stravodimou A, Hugelshofer S, Peters S, Hullin R, Obeid M
J Immunother CancerSpatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas
Goldschmid H, Kluck K, Ball M, Kirchner M, Allgäuer M, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, Yong TTK, Schirmacher P, Peters S, Thomas M, Christopoulos P, Budczies J, Stenzinger A, Kazdal D
Lung CancerCarrières en oncologie et leadership féminin : les progrès sont-ils au point mort ?
Peters S, Addeo A, Aapro M
Rev Med SuissePopulation pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance
Hwang M, Chia YL, Zheng Y, Chen CC, He J, Song X, Zhou D, Goldberg SB, Siu LL, Planchard D, Peters S, Mann H, Krug L, Even C
Br J Clin PharmacolImmunotherapy-based combinations in metastatic NSCLC
Desai A, Peters S
Cancer Treat RevAdjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
Kris MG, Mitsudomi T, Peters S
Transl Lung Cancer ResA neutrophil response linked to tumor control in immunotherapy
A neutrophil response linked to tumor control in immunotherapy. Gungabeesoon J, Gort-Freitas NA, Kiss M, Bolli E, Messemaker M, Siwicki M, Hicham M, Bill R, Koch P, Cianciaruso C, Duval F, Pfirschke C, Mazzola M, Peters S, Homicsko K, Garris C, Weissleder R, Klein AM, Pittet MJ
CellSotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor C, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators
LancetDurvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T, POSEIDON investigators
J Clin OncolTreatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B
J Thorac OncolOncology: what's new in 2022
[Oncology: what's new in 2022]. Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Digklia A, Wagner AD, Zaman K, Peters S, Stravodimou A
Rev Med SuisseAdherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher JP, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner AD, Csajka C, Schneider MP
CancersAssessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RA
Lung CancerDostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Lim SM, Peters S, Ortega Granados AL, Pinto GDJ, Fuentes CS, Lo Russo G, Schenker M, Ahn JS, Reck M, Szijgyarto Z, Huseinovic N, Zografos E, Buss E, Stjepanovic N, O'Donnell S, de Marinis F
Nat CommunPatient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M
Lung CancerDisparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U
Lung CancerLung cancer screening : towards the implementation of a pilot project in Switzerland
Bongard C, Rey Cobo J, Messe R, Noirez L, Lovis A, Krueger T, Peters S, Pozzessere C, Selby K, Von Garnier C
Rev Med SuisseSafety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Popat S, Peters S, Memaj A, Nathan F, Aanur N, Borghaei H
J Thorac Oncol
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment
Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, Krueger T, Perentes JY, Schmid RA, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel RA, Rothschild SI, Hayoz S, Opitz I
J Thorac Cardiovasc SurgPrognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort
Bubendorf L, Zoche M, Dafni U, Rüschoff JH, Prince SS, Marti N, Stavrou A, Kammler R, Finn SP, Moch H, Peters S, Stahel RA
Lung CancerCorrection to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I, ETOP Mesoscape consortium
Mod PatholImmune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
Cortellini A, Dettorre GM, Dafni U, Aguilar-Company J, Castelo-Branco L, Lambertini M, Gennatas S, Angelis V, Sita-Lumsden A, Rogado J, Pedrazzoli P, Viñal D, Prat A, Rossi M, Berardi R, Alonso-Gordoa T, Grisanti S, Dimopoulou G, Queirolo P, Pradervand S, Bertuzzi A, Bower M, Arnold D, Salazar R, Tucci M, Harrington KJ, Mazzoni F, Mukherjee U, Tsourti Z, Michielin O, Pommeret F, Brunet J, Vincenzi B, Tonini G, Patriarca A, Biello F, Krengli M, Tabernero J, Pentheroudakis G, Gennari A, Peters S, Romano E, Pinato DJ
J Immunother CancerPatients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey
Arditi C, Eicher M, Colomer-Lahiguera S, Bienvenu C, Anchisi S, Betticher D, Dietrich PY, Duchosal M, Peters S, Peytremann-Bridevaux I
Eur J Cancer Care (Engl)Minus Times Minus Equals Plus
Haanen J, Peters S
J Clin OncolAlectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans AC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R, ETOP 12-17 ALERT-lung Collaborators
Lung CancerPembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S, EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators
Lancet OncolFirst communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
Digklia A, Boughdad S, Homicsko K, Dromain C, Trimech M, Dolcan A, Peters S, Prior J, Schaefer N
J Immunother CancerSystematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M
J Immunother CancerPerspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Ascierto PA, Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitvogel L, Puzanov I, Thurin M
J Transl MedAtezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T
Nat MedAn International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ, On Behalf Of The Esmo Co-Care
Cancers (Basel)Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors
Hibar DP, Demetri GD, Peters S, Davies J, Humblet O, Maund SL, Perez L
PLoS OneCoronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J, TERAVOLT study group
JTO Clin Res RepSetting the Benchmark for KRAS(G12C) -Mutated NSCLC
Passaro A, Peters S
N Engl J MedAddressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Peters S, Paz-Ares L, Herbst RS, Reck M
J Immunother CancerA prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA
Lung CancerOccupational cancers: essentials for the general practioners
Krief P, Cohidon C, Turcu V, Rinaldo M, Kamara M, Koller M, Zyska Cherix A, Senn N, Peters S
Rev Med SuisseTargeted therapies and non-small cell carcinomas : novelties
Stauber R, Gro S L, Nguyen-Ngoc T, Mederos N, Bouchaab H, Peters S, Abdelhamid K
Rev Med SuisseCirculating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial
Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, Noé J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT
Clin Cancer ResHumoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, Stevenel C, Hottinger R, Pythoud C, Coutechier L, Molinari L, Trono D, Ribi C, Gottardo R, Fenwick C, Pascual M, Duchosal MA, Peters S, Pantaleo G
JAMA OncolFirst-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P
Lung CancerCheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small
De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S
Clin Lung CancerA Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERAVOLT study group
J Thorac OncolEstablishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Frost H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Huddar P, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Rogado J, Romano E, Rowe M, Sekacheva M, Sheehan R, Stevenson J, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Palmieri C, Landers D, Cooksley T; ESMO Co-Care; Dive C, Freitas A, Armstrong AC
JCO Clin Cancer InformHistological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
Ball M, Christopoulos P, Kirchner M, Allgäuer M, Brandt R, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, Kriegsmann M, Schirmacher P, Peters S, Thomas M, Stenzinger A, Kazdal D
Cold Spring Harb Mol Case StudDelayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib
Haeller CN, Khamsy L, Kloepper J, Schiappacasse L, Bouchaab H, Peters S, Schalenbourg A
Klin Monbl AugenheilkdExpression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, Opitz I, ETOP Mesoscape consortium
Mod PatholA differential process mining analysis of COVID-19 management for cancer patients
Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S, Michielin O
Front Oncol
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians
Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, IJzerman M, Solomon BJ
ESMO OpenRecent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F
J Thorac OncolCombined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M
Lung CancerPilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment: A Cluster-Randomized Study (Symptom Navi Pilot Study)
Bana M, Ribi K, Peters S, Kropf-Staub S, Näf E, Zürcher-Florin S, Stoffel B, Blaeuer C, Borner M, Malin D, Biber R, Betticher D, Kuhn-Bächler T, Cantoni N, Seeger T, Bütikofer L, Eicher M, Symptom Navi Program Group
Cancer NursQuantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC
Vuong D, Bogowicz M, Wee L, Riesterer O, Vlaskou Badra E, D'Cruz LA, Balermpas P, van Timmeren JE, Burgermeister S, Dekker A, De Ruysscher D, Unkelbach J, Thierstein S, Eboulet EI, Peters S, Pless M, Guckenberger M, Tanadini-Lang S
Sci Rep(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M
J Immunother CancerThe CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19
Li A, Kuderer NM, Hsu CY, Shyr Y, Warner JL, Shah DP, Kumar V, Shah S, Kulkarni AA, Fu J, Gulati S, Zon RL, Li M, Desai A, Egan PC, Bakouny Z, Kc D, Hwang C, Akpan IJ, McKay RR, Girard J, Schmidt AL, Halmos B, Thompson MA, Patel JM, Pennell NA, Peters S, Elshoury A, de Lima Lopes G, Stover DG, Grivas P, Rini BI, Painter CA, Mishra S, Connors JM, Lyman GH, Rosovsky RP, CCC19 consortium
J Thromb HaemostSAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Swiss Group for Clinical Cancer Research (SAKK)
J Clin OncolImaging Features of Pulmonary Immune-related Adverse Events
Pozzessere C, Lazor R, Jumeau R, Peters S, Prior JO, Beigelman-Aubry C
J Thorac OncolPreselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging
Oliveira C, Amstutz F, Vuong D, Bogowicz M, Hüllner M, Foerster R, Basler L, Schröder C, Eboulet EI, Pless M, Thierstein S, Peters S, Hillinger S, Tanadini-Lang S, Guckenberger M
EJNMMI ResNeutrophils in the era of immune checkpoint blockade
Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N
J Immunother CancerPatient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, Le Moulec S, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA
Clin Lung CancerOptimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data
Bandiera C, Cardoso E, Locatelli I, Digklia A, Zaman K, Diciolla A, Cristina V, Stravodimou A, Veronica AL, Dolcan A, Sarivalasis A, Liapi A, Bouchaab H, Orcurto A, Dotta-Celio J, Peters S, Decosterd L, Widmer N, Wagner D, Csajka C, Schneider MP
JMIR Res ProtocLurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M, Digklia A
Front OncolNongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, Peters S, Krueger T, Gfeller D, Riggi N, Oricchio E, Letovanec I, Ciriello G
Cancer DiscovTreatment Decisions for Patients with Cancer during the COVID-19 Pandemic
Labaki C, Peters S, Choueiri TK
Cancer DiscovPrognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, Biernat W, Verbeken E, Hernandez-Losa J, Marchetti A, Cheney R, Warth A, Speel EM, Quinn AM, Monkhorst K, Jantus-Lewintre E, Tischler V, Marti N, Dimopoulou G, Molina-Vila MA, Kammler R, Kerr KM, Peters S, Stahel RA, European Thoracic Oncology Platform Lungscape Investigators
J Thorac OncolOncologie et pandémie de Covid-19 : les patients au cœur des enjeux
Dietrich PY, Aapro M, Peters S
Rev Med SuisseGLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy
Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, Perentes JY, Peters S, Abel ED, Kirsch DG, Rathmell JC, Vozenin MC, Meylan E
Cancer ResTelephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital
Jankovic J, Da Silva Lopes AM, Morez A, Darnac C, Demicheli R, Dalla-Vale M, Lauriers N, Garcia Sanchez J, Bouchaab H, Ninane F, Peters S, Michielin O, Pradervand S, Eicher M, Colomer-Lahiguera S
Rev Med SuisseOvercoming therapy resistance in EGFR-mutant lung cancer
Passaro A, Jänne PA, Mok T, Peters S
Nat CancerThe Promising Evolution of Targeted Therapeutic Strategies in Cancer
Peters S, Mok T, Passaro A, Jänne PA
Cancer DiscovOncoAlert Round Table Discussions: The Global COVID-19 Experience
Morgan G, de Azambuja E, Punie K, Ades F, Heinrich K, Personeni N, Rahme R, Ferrara R, Pels K, Garassino M, von Bergwelt-Baildon M, Lopes G, Barlesi F, Choueiri TK, Burris H, Peters S
JCO Glob OncolConventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma
Kazdal D, Rempel E, Oliveira C, Allgäuer M, Harms A, Singer K, Kohlwes E, Ormanns S, Fink L, Kriegsmann J, Leichsenring M, Kriegsmann K, Stögbauer F, Tavernar L, Leichsenring J, Volckmar AL, Longuespée R, Winter H, Eichhorn M, Heußel CP, Herth F, Christopoulos P, Reck M, Muley T, Weichert W, Budczies J, Thomas M, Peters S, Warth A, Schirmacher P, Stenzinger A, Kriegsmann M
Transl Lung Cancer ResA Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, Scheuring U, Peters S, Rizvi NA, Brohawn PZ, Ranade K, Higgs BW, Banks KC, Chand VK, Raja R
Clin Cancer ResFast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S
J Immunother CancerSeverity of COVID-19 in patients with lung cancer: evidence and challenges
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S
J Immunother CancerStrength in numbers: predicting response to checkpoint inhibitors from large clinical datasets
Stenzinger A, Kazdal D, Peters S
CellOutcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT
J Thorac OncolProgression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platf
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D
J Thorac OncolPersonalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis
Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M
J Thorac OncolFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G
Lancet2020 oncology update
Dei Tos G, Galli Vareia I, Huber A, Wolf B, Diciolla A, Herrera Gomez RG, Wagner D, Digklia A, Bouchaab H, Cristina V, Stravodimou A, Zaman K, Sarivalasis A, Berthold D, Peters S, Perrinjaquet C, Kloepper J, Jankovic J
Rev Med SuisseA gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Fröhling S, Peters S, Seliger B, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A
OncoimmunologyImpact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
Forster C, Doucet V, Perentes JY, Abdelnour-Berchtold E, Zellweger M, Faouzi M, Bouchaab H, Peters S, Marcucci C, Krueger T, Rosner L, Gonzalez M
Transl Lung Cancer ResAbscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab
Mampuya WA, Bouchaab H, Schaefer N, Kinj R, La Rosa S, Letovanec I, Ozsahin M, Bourhis J, Coukos G, Peters S, Herrera FG
Clin Transl Radiat OncolBlood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM
J Thorac OncolCOVID-19 and Cancer: A Review of the Registry-Based Pandemic Response
Desai A, Mohammed TJ, Duma N, Garassino MC, Hicks LK, Kuderer NM, Lyman GH, Mishra S, Pinato DJ, Rini BI, Peters S, Warner JL, Whisenant JG, Wood WA, Thompson MA
JAMA OncolEarly discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer
Forster C, Perentes JY, Ojanguren A, Abdelnour-Berchtold E, Zellweger M, Bouchaab H, Peters S, Krueger T, Gonzalez M
Interact Cardiovasc Thorac Surg
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J
Lung CancerLung cancer screening in Switzerland: Who? How? When?
Casutt A, Lovis A, Selby K, Noirez L, Peters S, Beigelman-Aubry C, Krueger T, Soccal PM, Von Garnier C
Rev Med SuisseThe METeoric rise of MET in lung cancer
Friedlaender A, Drilon A, Banna GL, Peters S, Addeo A
CancerCOVID-19 and Cancer: Current Challenges and Perspectives
Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, Painter CA
Cancer CellTumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence
Passaro A, Stenzinger A, Peters S
Cancer CellSupporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience
Trama A, Proto C, Whisenant JG, Torri V, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Mazieres J, Soo RA, Leighl NB, Peters S, Wakelee H, Horn L, Hellmann M, Wong SK, Garassino MC, Baena J
Cancer CellLung cancer screening: what can we tell our patients while we await a screening program ?
Selby K, Gubelmann R, Lovis A, Bulliard JL, Beigelman-Aubry C, Casutt A, Peters S, Krueger T, Von Garnier C, Cornuz J
Rev Med SuisseGender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
Mederos N, Friedlaender A, Peters S, Addeo A
ESMO OpenOutcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ignatius Ou SH, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT
J Thorac OncolA Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOU
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, Von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA
J Thorac OncolUtilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL; COVID-19 and Cancer Consortium
Cancer DiscovComparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients
Vuong D, Bogowicz M, Denzler S, Oliveira C, Foerster R, Amstutz F, Gabryś HS, Unkelbach J, Hillinger S, Thierstein S, Xyrafas A, Peters S, Pless M, Guckenberger M, Tanadini-Lang S
Med PhysThe Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Papotti M, Pelosi G, Poleri C, Rekhtman N, Tsao M-S, Thunnissen E, Travis W, Yatabe Y, Yoshida A, Daigneault JB, Zehir A, Peters S, Wistuba II, Kerr KM, Longshore JW
J Thorac OncolSurvey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer
Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, Choueiri TK
JCO Glob OncolPembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR, KEYNOTE-604 Investigators
J Clin OncolGender gap: surveying the world for tomorrow
Garrido P, Tsang J, Peters S
ESMO OpenTreatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic
Dingemans AC, Soo RA, Jazieh AR, Rice SJ, Kim YT, Teo LLS, Warren GW, Xiao SY, Smit EF, Aerts JG, Yoon SH, Veronesi G, De Cobelli F, Ramalingam SS, Garassino MC, Wynes MW, Behera M, Haanen J, Lu S, Peters S, Ahn MJ, Scagliotti GV, Adjei AA, Belani CP
J Thorac OncolCOVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L, TERAVOLT investigators
Lancet OncolClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 and Cancer Consortium
LancetThe COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer
Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, Choueiri TK
Cancer CellTERAVOLT: Thoracic Cancers International COVID-19 Collaboration
Whisenant JG, Trama A, Torri V, De Toma A, Viscardi G, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Soo RA, Leighl NB, Peters S, Wakelee H, Garassino MC, Horn L
Cancer CellImpact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D
Lung CancerChallenges in lung cancer therapy during the COVID-19 pandemic
Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, Altomonte M, Vegni V, Gridelli C, Reck M, Rizvi N, Maio M
Lancet Respir MedRechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M
J Immunother CancerESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
Passaro A, Addeo A, Von Garnier C, Blackhall F, Planchard D, Felip E, Dziadziuszko R, de Marinis F, Reck M, Bouchaab H, Peters S
ESMO OpenUne période de craintes et de défis : vers un monde meilleur ?
Dietrich PY, Aapro M, Peters S
Rev Med SuisseSmall-cell lung cancer: management and novelties
Abdelhamid K, Kakourou A, Degrauwe N, Nikolopoulou A, Bouchaab H, Peters S, Nguyen-Ngoc T, Mederos N
Rev Med SuisseDescribing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool
Gerber A, Da Silva Lopes A, Szüts N, Simon M, Ribordy-Baudat V, Ebneter A, Perrinjaquet C, Gaignard ME, Nicodet D, Betticher D, Bula G, Cote M, Duchosal MA, Berret PA, Dietrich PY, Brennan C, Decosterd S, Ferreira Nobre S, Peters S, Koelliker R, Ninane F, Jeitziner MM, Colomer-Lahiguera S, Eicher M
Health Sci RepProgrammed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungs
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA, European Thoracic Oncology Platform Lungscape Consortium
Mod PatholLurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L
Lancet OncolDurvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman A-M, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators
JAMA OncolOncology: navigating the COVID-19 Pandemic and Steer the Course
Zimmermann S, Dietrich PY, Michielin O, Betticher D, Peters S
Rev Med SuisseQuantifying potential confounders of panel-based tumor mutational burden (TMB) measurement
Budczies J, Kazdal D, Allgäuer M, Christopoulos P, Rempel E, Pfarr N, Weichert W, Fröhling S, Thomas M, Peters S, Endris V, Schirmacher P, Stenzinger A
Lung CancerRelationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study
Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Bourhis J, Prior JO, Peters S, Lazor R, Beigelman-Aubry C
ERJ Open ResEvolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R
J Thorac OncolTargeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S, Früh M, Peters S
Lancet OncolJournée du cancer : mobiliser autour de la prévention
Peters S, Dietrich PY
Rev Med SuisseDevelopment and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi© Programme
Bana M, Ribi K, Kropf-Staub S, Näf E, Schramm MS, Zürcher-Florin S, Peters S, Eicher M
Eur J Oncol NursAdvances in Oncology 2019
Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A
Rev Med SuissePrimary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary
Malebranche M, Sarivalasis A, Peters S, Mathevet P, Cornuz J, Bodenmann P
J Prim Care Community HealthImpact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians
Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, I Jzerman M, Solomon B
ESMO OpenRadiomics Feature Activation Maps as a New Tool for Signature Interpretability
Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M
Front OncolTargeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S
J Clin Oncol
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S
Lung CancerNivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS
N Engl J MedSpatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts
Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A
J Thorac OncolAppraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade
Zimmermann S, Peters S
JAMA OncolAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Nat Rev Clin OncolPreanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis
Ascierto PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N
J Mol Diagn(18)F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N
Eur J Nucl Med Mol ImagingImmune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Dafni U, Tsourti Z, Vervita K, Peters S
Lung CancerImplementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study)
Bana M, Ribi K, Kropf-Staub S, Zürcher-Florin S, Näf E, Manser T, Bütikofer L, Rintelen F, Peters S, Eicher M
BMJ OpenUpdated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT
J Thorac OncolAfatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S
J Thorac OncolThe new management options for lung cancer in the immunotherapy era
Meganem H, Socianu RM, Bouchaab H, Mederos N, Nguyen-Ngoc T, Peters S, Dolcan A
Rev Med SuisseDe sérieuses préoccupations qui ne cachent pas nos espoirs
Aapro M, Peters S, Dietrich PY
Rev Med SuisseImmunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Martinez P, Peters S, Stammers T, Soria JC
Clin Cancer ResA retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R, Lungscape Consortium
Lung CancerPreoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S, Swiss Group of Clinical Cancer Research (SAKK)
Br J CancerAfatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT
Eur J CancerBrain metastases
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD
Nat Rev Dis PrimersOncology, what's new in 2018
Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, Stravodimou A
Rev Med SuisseTrastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE
Clin Cancer ResMultimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M, Swiss Group for Clinical Cancer Research (SAKK)
J Thorac OncolCharacterisation of rare haematological immune-related toxicities
Haanen JB, Peters S
Lancet HaematolNew therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Lancet OncolDefinition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S
J Thorac OncolMultiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient
Pillonel V, Dunet V, Hottinger AF, Berthod G, Schiappacasse L, Peters S, Michielin O, Aedo-Lopez V
J Immunother Cancer
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
J Clin OncolEffect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015
Lazzarino T, Martenet S, Mamin R, Du Pasquier RA, Peters S, Perreau M, Muller O, Hugli O, Cavassini M, Darling KEA
BMJ OpenGender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S
ESMO OpenReport on the status of women occupying leadership roles in oncology
Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S
ESMO OpenDelineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC
Zimmermann S, Peters S
J Thorac OncolAcceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration
Serena A, Dwyer AA, Peters S, Eicher M
J Nurs ScholarshManagement of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy
Peters S, Zimmermann S
Curr Treat Options OncolImmune Checkpoint Inhibitors in the Management of Lung Cancer
Zimmermann S, Peters S, Owinokoko T, Gadgeel SM
Am Soc Clin Oncol Educ BookDe vrais espoirs et de sérieuses préoccupations
Peters S, Dietrich PY, Aapro M
Rev Med SuisseGenomic Features of Response to Combination Immunotherapy in Lung Cancer
Früh M, Peters S
Cancer CellEML4-ALK Variant Affects ALK Resistance Mutations
Früh M, Peters S
J Clin OncolRANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma
Faget J, Contat C, Zangger N, Peters S, Meylan E
J Thorac OncolEvaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S, European Thoracic Oncology Platform Lungscape Consortium
J Thorac OncolPD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Peters S, Kerr KM, Stahel R
Cancer Treat RevComputer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A
J Thorac OncolActivity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC
J Thorac Oncol
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators
N Engl J MedPhase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E
J Clin OncolFeasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study
Serena A, Dwyer A, Peters S, Eicher M
Eur J Oncol NursScientific Advances in Thoracic Oncology 2016
Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR
J Thorac OncolPatient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study
De Rossi N, Dattner N, Cavassini M, Peters S, Hugli O, Darling KEA
PLoS OneFirst-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators
N Engl J MedL’accès à l’innovation
Aapro M, Dietrich PY, Peters S
Rev Med SuisseErlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA, BELIEF collaborative group
Lancet Respir MedBevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF, Swiss Group for Clinical Cancer Research
Clin Lung CancerRandomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European T
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group
J Thorac OncolThe Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, Van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E
J Thorac OncolBiosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F
ESMO OpenNovel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C
ESMO OpenPrevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project
Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA, Lungscape Consortium
Lung CancerImmunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer
Rizvi NA, Peters S
N Engl J Med
Scientific Advances in Lung Cancer 2015
Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou S-H, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI
J Thorac OncolThe impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
Peters S, Bexelius C, Munk V, Leighl N
Cancer Treat RevEmerging Options After Progression During Crizotinib Therapy
Peters S
J Clin OncolApnea-like suppression of respiratory motion: First evaluation in radiotherapy
Péguret N, Ozsahin M, Zeverino M, Belmondo B, Durham AD, Lovis A, Simons J, Long O, Duclos F, Prior J, Denys A, Beigelman C, Sozzi WJ, Grant K, Gautier-Dechaud V, Peters S, Vienne M, Moeckli R, Bourhis J
Radiother OncolSurvival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy
Abdelnour-Berchtold E, Perentes JY, Ris HB, Beigelman C, Lovis A, Peters S, Krueger T, Gonzalez M
World J SurgSeeking New Approaches to Patients With Small Cell Lung Cancer
Pietanza MC, Zimmerman S, Peters S, Curran WJ Jr
Am Soc Clin Oncol Educ BookInvestigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I
Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE
OncologistCareer opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
ESMO Open
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Cierni, Weder W
Lancet OncolIs prescription of a therapy costing 150,000 CHF reasonable?
Peters S, von Moos R, Thurlimann B
Rev Med SuisseBRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer
Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S
J Thorac OncolTargeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J
J Thorac OncolBevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF, Swiss Group for Clinical Cancer Research
Clin Lung CancerPresent standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Zimmermann S, Peters S
Cancer Metastasis RevLung cancer. How much platinum-based chemotherapy is enough in NSCLC?
Peters S, Adjei AA
Nat Rev Clin OncolTreatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities
Wang X, Gronchi F, Bensimon M, Mercier T, Decosterd LA, Wagnières G, Debefve E, Ris HB, Letovanec I, Peters S, Perentes JY
Lasers Surg MedPatients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study
Favre-Bulle T, Baudat D, Darling KE, Mamin R, Peters S, Cavassini M, Hugli O
Swiss Med Wkly
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA, ETOP Lungscape Investigators
J Thorac OncolDramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient
Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O
Melanoma ResPrevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project
Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA
J Clin OncolOral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions
Peters S, Zimmermann S, Adjei AA
Cancer Treat Rev2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S, Panel Members, ESMO
Ann OncolComprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network
NatureIndications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
Zimmermann S, Dziadziuszko R, Peters S
Cancer Treat RevLow-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model
Perentes JY, Wang Y, Wang X, Abdelnour E, Gonzalez M, Decosterd L, Wagnieres G, van den Bergh H, Peters S, Ris HB, Krueger T
Transl OncolTargeted therapy in NSCLC driven by HER2 insertions
Peters S, Zimmermann S
Transl Lung Cancer ResCerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer
Voide C, Zimmermann S, Adjei AA, Betticher DC, Meuli R, Prod'hom G, Giulieri S, Peters S
J Thorac OncolALK inhibitors in the treatment of advanced NSCLC
Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F
Cancer Treat RevPan-HER inhibition in EGFR wild-type non-small-cell lung cancer
Peters S, Smit E
Lancet OncolInvestigating barriers in HIV-testing oncology patients. The IBITOP study: phase I
Merz L, Peters S, Zimmermann S, Cavassini M, Darling K
J Int AIDS Soc
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression
Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O
Clin Cancer ResPractical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer
Zimmermann S, Peters S
EJC SupplTreatment and detection of ALK-rearranged NSCLC
Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R
Lung CancerDramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma
Peters S, Michielin O, Zimmermann S
J Clin OncolImpact of induction therapy on airway complications after sleeve lobectomy for lung cancer
Gonzalez M, Litzistorf Y, Krueger T, Popeskou SG, Matzinger O, Ris HB, Gronchi F, Lovis A, Peters S
Ann Thorac SurgLung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O
J Clin OncolTesting for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives
Lee JA, Bubendorf L, Stahel R, Peters S
Expert Rev Anticancer TherA dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Demierre N, Zoete V, Michielin O, Stauffer E, Zimmermann DR, Betticher DC, Peters S
Lung CancerTargeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer
Peters S, Meylan E
Curr Opin OncolVeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F, Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel R, Smit E
Lung CancerLung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib
Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J
Lung CancerStrategies for improving outcomes in NSCLC: a look to the future
Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA
Lung Cancer
Pulmonary sarcoid-like granulomatosis induced by ipilimumab
Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O
J Clin OncolMET: a promising anticancer therapeutic target
Peters S, Adjei AA
Nat Rev Clin OncolPhotodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density
Wang Y, Gonzalez M, Cheng C, Haouala A, Krueger T, Peters S, Decosterd LA, van den Bergh H, Perentes JY, Ris HB, Letovanec I, Debefve E
Lasers Surg MedOutcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R
Eur J CancerHIV testing practices by clinical service before and after revised testing guidelines in a Swiss University Hospital
Darling KE, Hugli O, Mamin R, Cellerai C, Martenet S, Berney A, Peters S, Du Pasquier RA, Bodenmann P, Cavassini M
PLoS OneTherapeutic advances in non-small cell lung cancer
Vallières E, Peters S, Van Houtte P, Dalal P, Lim E
ThoraxImpact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome
Perentes J, Bopp S, Krueger T, Gonzalez M, Jayet PY, Lovis A, Matzinger O, Ruffieux C, Ris HB, Letovanec I, Peters S
Ann Thorac SurgMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, ESMO Guidelines Working Group
Ann Oncol
Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach
Stupp R, Betticher D, Ris HB, Peters S, Pless M
J Clin OncolExtrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors
Gonzalez M, Krueger T, Perentes JY, Matzinger O, Peters S, Ris HB
Ann Thorac Surg
Solitary choriocarcinoma in the lung
Berthod G, Bouzourene H, Pachinger C, Peters S
J Thorac OncolPhotodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs
Cheng C, Debefve E, Haouala A, Andrejevic-Blant S, Krueger T, Ballini JP, Peters S, Decosterd L, van den Bergh H, Wagnieres G, Perentes JY, Ris HB
Lasers Surg Med
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M
Lancet OncolThalidomide in small cell lung cancer: wrong drug or wrong disease?
Rüegg C, Peters S
J Natl Cancer Inst
- (ouvre une nouvelle fenêtre)
- Suivant
- Précédent
- (ouvre une nouvelle fenêtre)
- Suivant
- Précédent